PERCHERON THERAPEUTICS LIMITED (PER)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PER - PERCHERON THERAPEUTICS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.079

01 Nov
2024

-0.002

OPEN

$0.08

-2.47%

HIGH

$0.08

2,892,361

LOW

$0.08

TARGET
$0.19 140.5% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
PER: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 1.4 - 1.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-1.4
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx1.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-10.1 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-123.27 %
Return on Invested Capital xxxxxxxxxxxxxxx-122.96 %
Return on Assets xxxxxxxxxxxxxxx-87.09 %
Return on Equity xxxxxxxxxxxxxxx-123.27 %
Return on Total Capital xxxxxxxxxxxxxxx-152.45 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-10.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx12 M
Price To Book Value xxxxxxxxxxxxxxx5.46

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx15 M
Research & Development xxxxxxxxxxxxxxx11 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

08/07/2024

1

Initiation of coverage with Speculative Buy

$0.14

77.22%

Bell Potter initiates coverage on biotechnology company Percheron Therapeutics with a Speculative Buy rating and 14c target.

Progress was slowed during the pandemic, notes the broker, but data from a phase 2b trial on ATL1102 in the second half of 2024 is expected to support further investment and a future partnering transaction.

The company is seeking to develop ATL1102 for the treatment of Duchenne Muscular Dystrophy (DMD).

DMD is a degenerative neuromuscular disorder caused by a mutation in the gene responsible for production of dystrophin (a protein essential to human life), explain the analysts.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Taylor Collison

08/04/2024

2

Outperform

$0.15

89.87%

Percheron Therapeutics has announced that 34 out of a total target of 45 patients have commenced treatment in its randomised Phase IIb trial of lead drug ATL1102 in non-ambulant patients with Duchenne muscular dystrophy (DMD).

Back in early-March, the broker had suggested Percheron was on track to report topline data from its randomised Phase IIb trial of lead drug ATL1102 in non-ambulant patients with Duchenne muscular dystrophy (DMD) around the end of 2024.

Sufficiently positive results could support an application for marketing approval of ATL1102, explained the analyst at the time.

The Outperform rating and 15c target are maintained.

FORECAST
Taylor Collison forecasts a full year FY25 EPS of 0.80 cents.
Access Extra Coverage Research History >

PER STOCK CHART

FNArena News on PER

1
Australian Broker Call *Extra* Edition – Oct 10, 2024

Oct 10 2024 - Daily Market Reports
2
FNArena Corporate Results Monitor – 02-09-2024

Sep 02 2024 - Australia
3
Australian Broker Call *Extra* Edition – Jun 11, 2024

Jun 11 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Apr 08, 2024

Apr 08 2024 - Daily Market Reports
5
Rudi’s View: Healthcare Under The Scanner

Mar 13 2024 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps